Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 1
1999 1
2000 1
2006 1
2008 1
2009 5
2010 8
2011 11
2012 15
2013 15
2014 9
2015 6
2016 7
2017 9
2018 17
2019 8
2020 17
2021 15
2022 16
2023 15
2024 14
2025 18
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib.
Welslau M, Fasching PA, Semmler-Lins N, Mueller L, Belleville E, Rieger L, Uhrig S, Zahn MO, Lex B, Uleer C, Deuerling N, Hesse T, Langanke D, Häberle L, Tesch H. Welslau M, et al. Among authors: haberle l. Breast. 2025 Dec 23;85:104684. doi: 10.1016/j.breast.2025.104684. Online ahead of print. Breast. 2025. PMID: 41534416 Free article.
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T. Michel LL, et al. Among authors: haberle l. Eur J Cancer. 2025 Sep 9;227:115689. doi: 10.1016/j.ejca.2025.115689. Epub 2025 Aug 5. Eur J Cancer. 2025. PMID: 40780076 Free article.
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA. Beierlein M, et al. Among authors: haberle l. Int J Cancer. 2025 Dec 1;157(11):2363-2373. doi: 10.1002/ijc.70037. Epub 2025 Jul 11. Int J Cancer. 2025. PMID: 40641449 Free PMC article. Clinical Trial.
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study.
Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, Park-Simon TW, Häberle L, Uhrig S, Tome O, Spall T, Theuser AK, Ruebner M, Belleville E, Wallwiener D, Brucker SY, Hartkopf AD. Schneeweiss A, et al. Among authors: haberle l. J Cancer Res Clin Oncol. 2025 Jun 19;151(6):192. doi: 10.1007/s00432-025-06246-2. J Cancer Res Clin Oncol. 2025. PMID: 40536732 Free PMC article.
Trop2-expression in primary vulvar squamous cell carcinoma.
Stuebs FA, Knöll A, Hartmann A, Matek C, John N, Häberle L, Beckmann MW, Erber R, Bercebal C, Geppert CI. Stuebs FA, et al. Among authors: haberle l. Gynecol Oncol. 2025 May;196:78-84. doi: 10.1016/j.ygyno.2025.03.049. Epub 2025 Apr 3. Gynecol Oncol. 2025. PMID: 40184712 Free article.
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.
Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching PA, Harbeck N, Langanke D, Uhrig S, Häberle L, Fischer D, Hein A, Fehm TN, Goossens C, Terhaag J, Heilenkötter U, Dall P, Rudlowski C, Wuerstlein R, Aydogdu M, Keyver-Paik MD, Hammerle C, Deuerling N, Stickeler E, Aktas B, Belleville E, Thoma M, Ditsch N, Baila Y, Roos C, Mann C, Iuliano C, Brucker SY, Schneeweiss A, Hartkopf AD. Müller V, et al. Among authors: haberle l. Breast. 2025 Jun;81:104458. doi: 10.1016/j.breast.2025.104458. Epub 2025 Mar 22. Breast. 2025. PMID: 40147402 Free PMC article.
183 results